アポリポプロテイン(a) イデンシ ハツゲン ワ TTTTA ハンプク ハイレツ ヨリモ 5\u27-ハプロタイプ ニ ヨッテ セイギョ サレル by 奥村  太郎 et al.
－ 17 －
Yamagata Med J  2014；32（1）：17 － 28
Introduction
Lipoprotein(a) [Lp(a)] is a low density lipoprotein 
(LDL)-like particle containing apolipoprotein B-100, 
that is covalently attached to a high-molecular-
weight glycoprotein, apolipoprotein(a) [apo(a)] 
by a disulfide bond1). Plasma levels of Lp(a) vary 
among normal subjects from <1 to more than 200 
mg/dl over a range of 1,000-fold. This feature is 
not observed in other human plasma proteins. A 
high concentration of Lp(a) in serum/plasma is 
an independent risk factor for atherothrombotic 
diseases, such as ischemic heart disease (IHD) and 
cerebral infarction2). 
Apo (a )  shares  homologous  domains  with 
plasminogen, including multiple tandem repeats 
of the kringle 4 (K4) domain followed by a single 
copy of kringle 53). Apo(a) is coded by the apo(a) 
gene4) which belongs to the plasminogen-apo(a) 
gene family5,6). The apo(a) gene accounts for over 
90% of the inter-individual variation in plasma 
Lp(a) concentrations7). Plasma Lp(a) levels inversely 
correlate with apo(a) isoform sizes; i.e. with the 
variable numbers of tandem K4 repeats8,9), i.e. 
type 2 kringle IV (KIV-2) of the apo(a) gene. The 
proportion of Lp(a) variance determined by KIV-2 
repeats has been estimated to be more than 40% in 
Caucasians7,10). 
  However, even individuals having the same 
KIV-2 repeat show wide variation in plasma 
Lp(a) levels11). It has been reported that there 
could be up to a 200-fold difference in the Lp(a) 
concentrations associated with the same isoform12). 
Two earlier studies13,14) also concluded that the 
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A high plasma level of lipoprotein(a), Lp(a), is recognized as an independent risk factor for various 
atherothrombotic diseases. Lp(a) concentrations are under genetic control, especially by the sizes 
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Thus, we explored the relationship between 5-FL haplotypes and PNRs among Japanese individuals. 
Strong linkage disequilibrium was observed between the haplotypes and PNRs. 8 PNRs and 9 PNRs 
were associated with types A and C (8-A and 8-C) and type D (9-D), respectively. 8-C had higher 
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reporter assays revealed that the difference in transcriptional efficiency of apo(a) gene between 8-C 
and 8-D was more distinct than that between 8-D and 9-D. Gel sift assays also suggested that 8-C 
had higher binding affinity to transcription factors than 9-D. Accordingly, the 5-FL haplotype 
rather than the PNR plays an important role in regulating plasma Lp(a) concentrations.
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contribution of apo(a) size polymorphisms to 
the Lp(a) concentrations were only 9.7 and 9%, 
respectively. Plasma Lp(a) concentrations are 
determined not by the rate of catabolism but by its 
rate of production15,16). Thus, these results indicate 
that plasma Lp(a) levels may be regulated by other 
factors/mechanisms of the apo(a) gene, such as 
transcription and protein translation.
In previous studies17,18), we reported the presence 
of single nucleotide polymorphisms (SNPs) in 
the 5’-flanking region (5-FL) of the apo(a) gene: 
nucleotides G/A at position -772, C/T at +93, and 
G/A +121, etc. We sub-classified the 5-FL of the 
apo(a) gene into four haplotypes (A to D) by a 
combination of these three SNPs: type A; G-C-G, 
type B; A-C-G, type C; A-C-A, type D; A-T-G. 
Homozygotes of type C (type CC) had significantly 
higher plasma Lp(a) concentrations than those 
of type D (type DD), and the relative expression 
activity of type C in an in vitro assay system was 
approximately three times higher than that of type 
D, which was consistent with the in vivo results18). 
These data suggest that the 5-FL haplotype of 
the apo(a) gene directly affects the transcriptional 
efficiency of its expression and plays a role in 
regulating plasma Lp(a) levels.
  I n  a d d i t i o n ,  t h e  n u m b e r  o f  T T T T A 
pentanucleotide repeats (PNRs) starting at -1373 
bp (position -1231 relative to the start site of 
transcription) from the translation initiation codon 
(position +121) has been reported to have an effect 
on Lp(a) concentrations, which is independent of 
the apo(a) isoform13,19-22). A significant negative 
correlation between the number of TTTTA 
repeats and plasma Lp(a) levels was observed in 
Caucasians19). As to each SNP in the 5-FL of the 
apo(a) gene, other investigators20) found a strong 
linkage disequilibrium between a SNP (i.e. +93 C/T) 
and the PNRs in Caucasians. However, it has been 
unknown which of these polymorphisms affects 
plasma Lp(a) levels most, and the relationship 
between the 5-FL haplotypes and the PNRs 
remains uncertain. Accordingly, the present 
study was carried out to elucidate the relationship 
between the 5-FL haplotypes and the PNRs on 
plasma Lp(a) levels in the Japanese population 
and transcriptional activity of the apo(a) gene by 
using a transient transfection assay and luciferase 
expression vectors. 
Methods 
Subjects and DNA samples 
This study was approved by the institutional 
review board of the Yamagata University School 
of Medicine. All the procedures were conducted 
in accordance with the Declaration of Helsinki. 
Informed consent was obtained from all the 
Japanese subjects including patients with IHD 
(n=85) and normal healthy controls (n=98). All 
IHD cases were evaluated by cardiologists. Blood 
samples were collected into tubes containing 
EDTA. Plasma was separated immediately by 
centrifugation, divided into aliquots and stored at 
-80℃ until determination of Lp(a) levels and apo(a) 
isoforms was carried out. Genomic DNA was 
prepared from leukocytes by phenol extraction. 
Measurement of plasma Lp(a) levels 
Plasma Lp(a) concentrations were measured by 
the latex-enhanced turbidimetric immunoassay 
method (Sanwa Chemical Laboratory, Nagoya, 
Japan) using an automated biochemical analyzer, 
COBAS MIRA Plus (Roche Diagnostics, Tokyo, 
Japan). One mg/dl is the lowest limit of detection 
according to the manufacturer’s manual. 
 
Apo(a) phenotyping 
A p o ( a )  i s o f o r m s  w e r e  d e t e r m i n e d  b y 
immunoblotting as described previously23) with 
the following modifications. Five μl of plasma 
without delipidation was dissolved in 95μl of 
the sample buffer (125 mM Tris-HCl pH 6.8, 
containing 2% SDS, 0.02% bromophenol blue, 5% 
2-mercaptoethanol, and 15% glycerol) at 100℃ for 
3 min. A 10μl aliquot of this mixture was loaded 
onto a 8.5×8.5 cm vertical 1 mm thick gradient 
polyacrylamide gel with 1% SDS. A running gel 
composed of 3% polyacrylamide with 0.5% agarose 
was poured onto glass plates preheated to 60℃, 
and a stacking gel with 2.5% polyacrylamide was 
added. Electrophoresis was performed at 100 V for 
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3h. After electrophoresis, proteins were transferred 
to nitrocellulose membranes by semidry blotting 
for 2h at a constant current (100 mA). After 
protein transfer, the membrane was incubated 
with 5% BSA for 1h to block remaining protein-
binding sites. Both a primary mouse anti-apo(a) 
monoclonal antibody (Terumo, Tokyo, Japan) and 
a secondary alkine phosphate-conjugated anti-
mouse IgG antibody (E.Y Laboratory, San Mateo, 
CA) were diluted to 1/1000 in a blocking buffer.
Determination of the 5-FL SNPs and the number of PNRs 
Each SNP (-772 G/A, +93 C/T, and +121 G/A) 
was determined by an amplification refractory 
mutation system (ARMS) and rapid automated 
capillary electrophoresis (RACE) method as 
described previously24).  Fluorescent-labeled 
oligonucleotide primers for these three SNPs were 
designed: 
5’-FAM-CAACCTCCATCTCCTGTGTACG-3’ and 
5’-TET-GCAACCTC CATCTCCTGTGTACA-3’ for 
-772G/A, 
5’-FAM-AAAGTGTGTCCCAA TCCCAGAACG-3’ 
and 
5’-TET-AAAGTGTGTCCCAATCCCAGAACA- 3’ 
for +93 C/T, and 
5’-FAM-ATTTTGGGACTGGCCAGCATTGC-3’ 
and 
5’-TET-ATTTTGGGACTGGCCAGCATTGT-3’ 
for +121 G/A, respectively. The underlined 
bases in each primer represent the mismatch 
b a s e s  f o r  A R M S .  A  c o m m o n  u n l a b e l e d 
a n t i s e n s e  p r i m e r  f o r  - 7 7 2  G / A  w a s 
5’-AGGCCACGGCAGATGGATCA-3’, while a 
common sense primer for +93 C/T and +121G/A 
was 
5’-GACTAATCAGGAAAGATG AAGGTCT-3’. 
To determine each genotype by ARMS, 200-500 ng 
of genomic DNA was amplified by PCR in a 25μl 
reaction mixture containing 20 pmoles of each 
primer and 1 unit of Taq DNA polymerase (Sawady, 
Tokyo, Japan). The PCR cycle consisted of the 
following steps: initial 3 min denaturation at 94℃, 
followed by 30 sec denaturation at 94℃, 30 sec of 
annealing at an appropriate temperature, and 30 
sec of extension at 72℃ for 25 cycles. For RACE 
analysis, 1μl of each PCR product was mixed in a 
single tube with 0.5μl of GeneScan-500 TAMRA size 
standard (Applied Biosystems, Warrington, UK), 
and 15μl of deionized formamide (Amresco, Solon, 
OH), then heated at 95℃ for 2 min and immediately 
cooled on ice. 
  To determine the number of PNRs, a fragment 
including the PNRs was amplified by PCR from 
genomic DNA using the following primers: 
5’-GAATTCA TTTGCGGAAAG-3’ for sense, 
5’-CGTCAGTGCACTTCAACC-3’ for antisense. 
Amplification conditions consisted of 3 min 
denaturation at 94℃, followed by 30 sec of 
denaturation at 94℃, 30 sec of annealing at 50℃ 
and 30 sec of extension at 72℃ for 35 cycles. The 
PCR products underwent electrophoresis on 8% 
polyacrylamide gels at 120 V for 2.5h. SpreadexR 
polymer NAB (Elchrom Scientific, Switzerland) 
was mixed into polyacrylamide gels to increase 
the resolving power of the gels following the 
manufacturer’s instructions. We determined the 
frequency of the PNRs for each haplotype in a total 
of 309 Japanese subjects by combining the data of 
126 individuals in the previous studies17,18) and that 
of 183 individuals in the present study (Table 1).
Construction of luciferase expression plasmids
The 5 -FL region of  the  apo(a )  gene  from 
position -1301 to +140 (relative to the start 
site of transcription) was amplified by PCR 
using subjects’ genomic DNAs as templates. 
Oligonucleotide primers were designed to obtain 
two separate fragments: 
5’-GAAGGTACCTGCGGAAAGATTGATACTA
TG-3’ (TTTTA-Kpn) and 
5’-TGACAGAGCAAGAATGTCTCAGGAAAG-3’ 
(5FL-832) for amplification from -1301 to -832, 
5’-CTTGAATTCCCAAAGTGCTGGGATTACAG
AG-3’ (A2-53) and 
5’-TATGTTCCATGGTGGGACTGGCCAGCA
GT-3’ (5FL-Nco) for amplification from -1016 
to +150 (Kpn I and Nco I sites are underlined). 
Each PCR fragment was inserted into an EcoR 
V-digested pBluescript vector (pBlue -1301/-
832 and pBlue -1016/+150, respectively). The 
pBlue -1301/-832 and pBlue -1016/+150 plasmids 
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were digested with Kpn I/PflM I and PflM I/Nco 
I, respectively. These two fragments were then 
ligated by Ligation highR (Toyobo, Osaka, Japan) 
and subcloned into Kpn I/Nco I-digested pGL3-
Basic (Promega, Madison, WI), a promoterless 
luciferase reporter gene vector. Subcloned plasmids 
with Kpn  I/Nco  I-digested pGL3-B (pGL3-B 
-1301/+140) were designated as types A, C and D, 
corresponding to each of the 5-FL haplotypes17). 
The PCR products containing nucleotide positions 
-1016 to +150 were amplified by oligonucleotide 
p r i m e r s ,  5 ’ - C T T G G T A C C C C A A A G T G C 
TGGGATTACAGAG-3’ (A2-53/Kpn, Kpn I site 
underlined) and 5FL-Nco, and then subcloned into 
Kpn I/Nco I-digested pGL3-B similarly (pGL3-B 
-1016/+140). The nucleotide sequences of inserts 
in all vectors were verified by ABI PRISMTM 310 
genetic analyzer (Applied Biosystems, Foster City, 
CA) using BigDyeTM terminator cycle sequencing 
kits (Applied Biosystems).
Cell culture and DNA transfection 
HepG2 cells were maintained in culture in 60-
mm dishes with low glucose Dulbecco’s Modified 
Eagle Medium (Nikken Biomedical Laboratory, 
Kyoto, Japan) containing 10% fetal bovine 
serum (JRH biosciences, Lenexa, KS) and PSN 
antibiotic mixture (Gibco BRL, Gaithersburg, 
MD). For transient transfection, plasmids were 
purified by a QIAGEN plasmid maxi kit (Qiagen, 
Germany). 5×105 HepG2 cells were co-transfected 
by the calcium phosphate method with 20μg of a 
luciferase expression plasmid and 2.5μg of a pSV
β-galactosidase vector (Promega). In brief, the 
cells were cultured for 24h, following the addition 
of BES-buffered solution (pH 6.95). At 24h after 
transfection, the plates were washed by phosphate 
buffered saline (PBS) once, and replaced by the 
same medium. After incubation for an additional 
48h, the cells were washed with PBS twice and 
harvested using 300μl of a lysis reagent, LCβ PGC-
51 (Toyo Inki, Tokyo, Japan). Both the pGL3-B 
and pGL3-Control (Promega) vectors were used as 
negative and positive controls, respectively, for the 
expression experiments. 
Assays of luciferase and β-galactosidase activity. 
For measurement of luciferase activity,  a 
luminometer, Lumat LB 9507 (EG&G Berthold, 
Germany), was employed by mixing 20μl of the 
cell lysates and 100μl of the luciferase substrate 
solution (Toyo Inki). To determineβ-galactosidase 
activity, 20μl of cell lysates were mixed in a 96-
well plate with 220μl of 0.05M potassium phosphate 
buffer (pH 7.8), 30μl of 0.01M MgCl2, 40μl of 10 mM
ο-nitrophenyl-β-D-galactopyranoside (Sigma), 
and 3μl of 8.9M 2-mercaptoethanol. The plate 
was incubated at room temperature for 30 min 
and measured by absorption at 405 nm using 
Biolumin 960 (Molecular Dynamics, Sunnyvale, 
CA). Luciferase activity was normalized toβ
-galactosidase activity for each dish.
Preparation of nuclear extracts 
Nuclear extracts were prepared from 1×107 HepG2 
cells. After washing with PBS twice, the cells were 
lysed by 0.4 ml of a cytoplasmic lysis buffer (20 
mM HEPES pH 7.6, 10 mM NaCl, 1.5 mM MgCl2, 
0.2 mM EDTA, 1 mM DTT, 0.1% NP-40, and 20% 
glycerol), and centrifuged, then a supernatant 
fraction was removed. A nuclear pellet was 
incubated on ice for 30 min after adding 0.1 ml of 
nuclear lysis buffer (20 mM HEPES pH 7.6, 500 mM 
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 
0.1% NP-40, and 20% glycerol) and centrifuged. 
The supernatant was collected as nuclear extracts, 
aliquoted into tubes, and stored at -80℃. Protein 
concentrations were measured by a BCA protein 
assay reagent (Pierce, Rockford, IL) following the 
manufacturer’s instructions.
Electrophoretic mobility shift assay (EMSA)
Radioactively labeled DNA probes were prepared by 
PCR. The luciferase expression vector containing 
the romoter region of the apo(a) gene was amplified 
using the primers as follows: TTTTA-Kpn and 5FL-
Nco (32P -1301/+150), where an appropriate amount 
of [α-32P] dCTP (NEN Life Science Products, 
Boston, MA) was added to the PCR mixture. Then, 
the PCR products were purified using Quantum 
prep PCR kleen spin columns (Bio-Rad, Hercules, 
CA). Binding reaction was performed using 2 μg of 
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poly dI-dC, 2 μg of nuclear extracts, 1 x 104 cpm 32P 
labeled DNA probe, and a reaction buffer [25 mM 
HEPES-KOH (pH 7.9), 0.5 mM EDTA (pH 8.0), 50 
mM KCl, 10% glycerol, 0.5 mM DTT and 0.5 mM 
PMSF]. The reaction mixture was incubated for 
30 min at room temperature. After preheating for 
1 h at 100 V, EMSA was performed on a 4% non-
denaturing polyacrylamide gel in 0.5 x TBE for 2 
h at 4 ℃. Gels were subjected to autoradiography 
by a fluoro-image analyzer FLA-2000 (Fuji Film, 
Tokyo, Japan).
Statistical Analysis 
Statistical analysis was performed with a Stat 
View program (SAS Institute, San Francisco, 
CA) and SAS enterprise guide 4.3. Linkage 
disequilibrium was determined by a chi-square 
test. Linear regression analyses were performed 
to assess the relationship between Lp(a) levels and 
apo(a) phenotypes. All values concerning Lp(a) 
levels are shown in means±standard deviation 
(S.D.). Lp(a) concentrations between different 
groups were examined by the Kruskal-Wallis test. 
For a luciferase assay and EMSA, a paired t-test 
was performed. A p-value of <0.05 was considered 
to be statistically significant. 
Results
Relationship between plasma Lp(a) levels and the 5-FL 
haplotypes
Lp(a) levels were 13.5±12.3 and 19.3±18.4 mg/
dl (p=0.034) in healthy individuals (Normal, n=98) 
and cases with IHD (n=60), respectively. When 
two groups were combined, individuals of type CC 
(n=43) had significantly higher Lp(a) levels than 
those with type DD (n=9); 18.9±20.9 vs.10.5±
6.9 mg/dl (p=0.038), as reported earlier18). We also 
compared plasma Lp(a) levels of each haplotype in 
two groups. Lp(a) levels of type CC in IHD (n=22) 
were two-fold higher than those of type DD (n=6, 
26.3±26.0 vs.13.2±6.7 mg/dl, respectively), and 
the difference was statistically significant (p=0.04). 
This tendency was also shown in Normal (11.2±
9.1 vs. 5.1±3.3 mg/dl, p=0.28), although statistical 
significance was not obtained. It was of note that 
six subjects having markedly high plasma Lp(a) 
levels (greater than 50 mg/dl) were present in the 
IHD group, and five of them were homozygous for 
type C. 
Relationship between Lp(a) levels and apo(a) sizes 
As reported previously8,9), Lp(a) concentrations were 
found to correlate inversely with apo(a) protein 
sizes in Normal and IHD groups in the present 
study (data not shown). Especially, the lower-
molecular-weight (L-MW) isoform among two 
apo(a) isoforms of each individual was more closely 
correlated with plasma Lp(a) levels than the higher-
molecular-weight isoform, as reported previously23). 
Therefore, we examined the correlation between 
Lp(a) concentrations and L-MW isoforms in all 
groups and IHD patients having type CC and DD. 
We did not draw a figure for Normal because a 
very limited number of subjects with type DD (n=3) 
were available. Fig. 1A & C showed that plasma 
Fig. 1. Relationship between plasma Lp(a) levels and 
lower-molecular-weight (L-MW) apo(a) isoforms of 
individuals with haplotype CC (closed circles) or DD 
(open squires) in total (A) and in patients with IHD (C). For 
IHD, the regression line for type CC (n= 22): Lp(a) levels = 
143.44 – 0.17 × L-MW, R2= 0.61, p<0.0001. The regression 
line for type DD (n= 6). Lp(a) levels = 54.42 – 0.06 × L-MW, 
R2= 0.38, p= 0.19. Relationship between plasma Lp(a) 
levels and apo(a) L-MW isoforms in cases with 8/8 (closed 
triangles) and 9/9 ≦ (open diamonds) for the PNRs in total 
(B) and in patients with IHD (D). For IHD, the regression 
lines indicate for 8/8 and 9/9 ≦ for the PNRs, respectively. 
For 8/8 (n= 53) : Lp(a) levels = 109.41 – 0.13 × L-MW, R2= 
0.46, p<0.0001, for 9/9 ≦ (n= 7): Lp(a) levels = 60.89 – 
0.074 × L-MW, R2= 0.45, p= 0.10. An inverse relationship 
was demonstrated between Lp(a) levels and L-MW isoforms 
both for the 5-FL haplotypes and PNRs.
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Lp(a) levels were inversely correlated with apo(a) 
isoforms in both haplotypes. Lp(a) levels of type 
CC were higher than those of type DD, even when 
they had similar apo(a) sizes. These results are 
in concordance with the conclusion that apo(a) 
expression is affected by haplotypes, as previously 
reported18). 
  We then examined the relationship between 
Lp(a) levels and apo(a) sizes in homozygotes of 
8 PNRs (8/8) with those of equal to or greater 
than 9 PNRs (9/9≦) in all individuals and in IHD 
patients. The 9/9≦ PNRs contained homozygotes 
for 9 (9/9), heterozygotes for 9 and 10 (9/10), 
and heterozygotes for 9 and 11 (9/11). Lp(a) 
concentrations of the 8/8 PNRs were higher 
than those of the 9/9≦ genotypes in the subjects 
having similar apo(a) isoforms (Fig. 1B & D). 
However, the difference caused by the PNRs was 
less distinguished than the difference caused by the 
haplotypes. 
  In order to examine the effect of PNRs on plasma 
Lp(a) levels in Japanese, we directly compared 
Lp(a) levels of three different PNR groups (8/8, 
8/9 and 9/9≦). Lp(a) concentrations did not differ 
significantly with respect to the PNRs in total, 
Normal and patients with IHD (Fig. 2A-C; p=0.93-
0.08). 
Association between the 5-FL haplotypes and the PNRs
Since Lp(a) concentrations were related to both 
the 5-FL haplotypes and the number of PNRs, we 
determined the frequency of the PNRs for each 
haplotype in 309 Japanese subjects combining 
the data of previous studies17,18) (Table 1). Most 
subjects having type CC and homozygotes of type 
A contained the 8/8 genotype for PNRs; on the 
other hand, 70% of individuals with the type DD 
possessed 9/9 genotype. Therefore, an allele with 8 
PNRs was associated with types A and C, whereas 
a 9 PNRs allele linked to type D. Thus, there is a 
statistically significant association between each 
Fig. 2. Plasma Lp(a) levels in a total of 178 individuals (A), 
93 normal individuals (B), and 85 patients with IHD (C) as 
a function of the number of PNRs. There was no statistical 
difference in Lp(a) levels between samples with different 
numbers of PNRs.
Table 1. Numbers of the TTTTA-PNR among each 
haplotype in Japanese. 
Frequenc ies  are  shown in  parentheses .  L inkage 
disequilibrium was observed between the PNRs and the 5-FL 
haplotypes.  * ; p= 0.0004, ** ; p ＜ 0.0001.
Fig. 3. Effects of PNRs and haplotypes on transcriptional 
activity of the apo(a) promoter region. HepG2 cells were 
co-transfected with test plasmids and aβ-galactosidase 
vector as a control of transfection efficiency. Luciferase 
activity was indicated relative to that of haplotype A with 
PNR-8 (8-A; 100%). Values represent means±S.D. of 3 
independent experiments. A p-value of <0.05 was considered 
to be statistically significant. *, p < 0.05, **, p < 0.005, ***, p 
< 0.001.
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haplotype and a certain number of PNRs (Table 
1). An allele with 10 PNRs seemed to be related to 
type B, but the number of subjects was too small 
to draw a conclusion (only 3 heterozygotes of 
type B among 309 subjects). All cases having an 
allele with 11 PNRs were heterozygotes for type 
C. Accordingly, strong linkage disequilibrium 
between the 5-FL haplotypes and the PNRs was 
observed in this study.
Effect of the haplotypes and PNRs on transcriptional 
activity
To elucidate the relationship between the 5-FL 
haplotypes and the PNRs in vitro, we studied the 
promoter activity of 8-A, 8-C, 8-D and 9-D by 
a transient transfection assay. 8-D had 1.4-fold 
higher luciferase activity than 9-D (p=0.01) (Fig. 3). 
However, 8-C had 1.8-fold higher than 8-D (p=0.003) 
and 2.5-fold than 9-D (p=0.0006). This data indicates 
that 5-FL haplotypes affect the transcriptional 
efficiency of the apo(a) gene. 
Differential DNA-protein binding among the haplotypes
From the results shown above, we hypothesized 
that varying binding affinity to transcription 
factors would cause the difference of luciferase 
activity among the haplotypes. To test this 
hypothesis, we carried out an EMSA to examine 
which haplotype of  type C and D is  more 
competitive to labeled type A probe. Non-labeled 
DNA fragment of type C more significantly 
reduced the binding ability on labeled probe (32P 
-1301/+150) as compared to those of type D (Figs. 
4A & B). The ability of type A to compete for 
binding of nuclear proteins showed a halfway 
between type C and D (data not shown).
Discussion
Apo(a) gene expression is regulated mainly by 
liver-enriched Hepatocyte Nuclear Factor 1α
(HNF-1α)25). It is also reported that the 1.4 kb 
apo(a) 5-FL comprises two composite regulatory 
regions: a distal negative regulatory module 
(positions -1432 to -716) and a proximal tissue-
specific module (positions -716 to -616)26). The 
former module contains the polymorphic PNR 
at position -1231 and the latter locates consensus 
sequences for hepatocyte-specific transcription 
elements such as LF-A1, CEBP, and HNF-1α6), 
which is consistent with the fact that the apo(a) 
gene is exclusively expressed in the liver. These cis-
elements in the 5-FL and KIV-2 repeat control the 
Lp(a) levels in plasma27).
  As reported earlier, several SNPs (-772 G/A, 
+93 C/T, and +121 G/A) present in the 5-FL of 
the apo(a) gene comprise four haplotypes (A-D) 17), 
while the PNR exists upstream from these SNPs. 
Fig. 4. Inhibition by competitor supplementation on 
labeled type A probe. (A) EMSA for 5-FL of the apo(a) gene 
(-1301/+150). Labeled PCR products fortype A having the 
eight TTTTA repeats were incubated with 2 μg of nuclear 
extracts prepared from HepG2 cells (lane 1). In lane 8, 
no nuclear extracts were contained in a reaction mixture 
(negative control). For competition analysis, an unlabeled 
PCR fragment was added to labeled type A probe in 5, 10 
and 20-fold molar excess (lane 2 and 5, 3 and 6, and 4 and 
7, respectively). Number of TTTTA repeat used as unlabeled 
type C and D fragments were eight (8-C) and nine (9-D), 
respectively.
(B) Amounts of bound probe are expressed as a percentage 
of relative density to labeled type A probe (lane 1 in 
Fig 4a). Values represent means±S.D. of 5 independent 
experiments. Quantitative analysis was performed by 
a fluoro-image analyzer FLA-2000. Asterisks illustrate 
statistically significant differences between type C and type 
D (*, p<0.05).
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We demonstrated that the 5-FL haplotypes in 
part regulate apo(a) gene expression18). However, 
plasmid constructs in our previous experiments did 
not contain the region of the PNR. 
A number of studies demonstrated that the 
number of PNRs was negatively correlated with 
Lp(a) levels in vivo13,19-22,28,29). However, no difference 
was found in the transcriptional activity of 5-FL 
fragments containing 8 or 11 PNRs of the apo(a) 
gene in vitro where haplotypes of the fragments 
were not identified30). This is consistent with the 
report that 10 allelic apo(a) 5-FL fragments of 1.5 
kb containing 8 or 9 PNRs exhibit comparable 
promoter activities in HepG2 cells, although only 
the SNP at position -772 was specified31). In the 
present study, we have clearly shown that the 
5-FL haplotype rather than the PNR plays an 
important role in regulating the transcription of 
apo(a) gene (Fig. 3). Similar PNRs are also present 
in other human genes, for example, the β-globin 
gene32), where there are 4 to 6 repeats about 1.4 kb 
upstream from the ATG initiation codon as in the 
apo(a) gene. This variation in the number of PNRs 
has no effect on β-globin promoter activity.
  The reason why the number of PNRs is negatively 
correlated with Lp(a) levels in the previous reports, 
including European Caucasians, Japanese and 
Chinese, needs to be addressed. It is likely that 
PNRs are in strong linkage disequilibrium with 
the 5-FL haplotypes of apo(a) that affect its 
transcriptional activity; for example, 9 PNR is 
associated with the +93T SNP (Table 1), which is 
identical to Japanese haplotype D with the lowest 
transcriptional activity in vitro17,18). The strong 
linkage disequilibrium between 9 PNR and the T 
allele has also been reported in white Caucasians 
and Asian-Indian33), European Caucasians20), and 
Korean34). This +93C/T polymorphism, which 
introduces an upstream ATG codon and reduces 
in vitro translation35), showed a significant impact 
on Lp(a) levels in black Africans but not in 
Caucasians36). Alternatively, it is reported that 
there is significant linkage disequilibrium between 
the number of PNRs and that of KIV-2 repeats30,36) 
which are associated with particular Lp(a) levels. 
Experimental data have shown that the processing 
and secretion of apo(a) is a function of the 
number of KIV-2 repeats in vitro37). However, this 
assumption on the translational regulation is not 
in agreement with previous reports that the effect 
of the 5-FL PNRs on plasma Lp(a) concentrations 
was independent from the KIV-2 repeat/apo(a) 
size polymorphism in vivo19,20,22). Moreover, it has 
been shown that the PNR elements containing 5, 
8, and 10 repeats bind differently to transcription 
factors in a hepatocyte-specif ic  manner26), 
indicating that the effect of PNRs on plasma Lp(a) 
levels is mediated at least in part by apo(a) gene 
transcription rather than by its translation.
  It is of note that the 5-FL of the chimpanzee 
a p o ( a )  i s  9 8 %  h o m o l o g o u s  t o  i t s  h u m a n 
counterpart, and contains only 4 stable repeats 
for PNRs in common in the 1.4 kb region38). The 
chimpanzee promoter with 4 PNRs exhibited 
5-fold transcriptional activity to its human 
counterpart, while the mean plasma Lp(a) levels in 
the chimpanzee are more than 3 times higher than 
those observed in humans39). 
The nucleotide sequence of the apo(a) gene varies 
not only inter-individually but also between racial 
groups, e.g. SNPs/haplotypes17,33) and PNR19) in 
the 5-FL, KIV-2 repeat40,41) and coding sequences 
in exons42), and so on. Accordingly, it is essential 
to examine KIV-2 repeats/SNPs in each racial 
group in order to understand the relationship 
between genomic nucleotide sequences and their 
effects on the expression of the apo(a) gene under 
physiological and/or pathological conditions.
  Little is known about population-related SNPs 
in the apo(a) gene among Japanese. Although 
the difference of plasma Lp(a) levels between 
IHD patients with type CC and those with DD 
was not statistically significant, most subjects 
having markedly high plasma Lp(a) levels were 
homozygous for type C. These results suggest 
that the frequency of type CC may be high among 
subjects having markedly elevated Lp(a) levels. 
As expected, significantly elevated Lp(a) levels 
were also observed in Japanese patients with 
corticosteroid-induced osteonecrosis of the femoral 
Apo(a) gene is regulated by 5'-Haplotype
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head who had type CC43). 
Several studies suggested the 5-FL region of the 
apo(a) gene may mediate response to drugs and 
hormones. For example, retinoids were reported to 
lower apo(a) mRNA levels in primary hepatocyte 
cultures and a retinoid response element at -1036 
was shown to be responsible for this effect44). 
Aspirin also reduced apo(a) levels in a culture 
medium of human hepatocytes, and a promoter 
region extending from -30 to +138 was critical for 
this effect of aspirin45). Accordingly, mutations and 
SNPs in the 5-FL of the apo(a) gene may lead to 
differential responses to drugs and physiological 
substances among individuals, an important 
consideration for medicines that are designed 
specifically to target the advance of atherosclerosis 
and development of thrombosis. Since mutations/
SNPs are fairy different between racial groups17,36), 
it is important to examine them in each population.
There are several limitations in our present study. 
First, we have investigated only Japanese subjects, 
no Caucasians or black Africans. Mean Lp(a) levels 
in black African are known to be significantly 
higher than in other populations, and the apo(a) 
alleles with lower number of PNRs are more 
frequent in black Africans19). Accordingly, the 
relationship between 5-FL haplotypes and PNRs 
could be different in other racial groups, as well. 
Second, other research groups46,47) demonstrated 
that two additional apo(a) regulatory sites existed 
further upstream from the region we investigated 
in the present study. There is a possibility that 
these remote sequences may interact with the 
5-FL haplotypes or PNRs, and affect apo(a) gene 
expression. That being the case, the relationship 
between SNPs in these upstream sites to the 
transcriptional activity of the apo(a) gene has been 
demonstrated in vitro48). In particular, alleles with 
a G variant were associated with 70% higher Lp(a) 
levels than those with an A variant, and these A/
G SNPs were in linkage disequilibrium with the 
-772G/A and +93C/T SNPs in the apo(a) promoter. 
Nevertheless, all the known polymorphisms are not 
enough to explain the differences of over 200-fold in 
Lp(a) concentrations associated with apo(a) alleles 
of the same size. Recently, it has been reported that 
eight SNPs that were not associated with KIV-2 
repeats were associated with Lp(a) concentration, 
suggesting that the SNPs are related to an 
alternative mechanism for modifying Lp(a) 
concentration, such as efficiency of transcription 
or expression49). In addition, a meta-analysis has 
recently revealed no candidate genes outside the 
apo(a) gene to have an effect on Lp(a) levels50).
In conclusion, we have demonstrated that the 
5-FL haplotypes rather than the PNRs in the 
apo(a) gene’s promoter region directly control its 
expression. We have also shown that PNRs are 
merely related by linkage disequilibrium with the 
5-FL haplotypes. The haplotypes may have some 
clinical significance, if differential responses to 
drugs and inflammatory agents were observed in 
patients. Further investigations will be carried out 
in order to explore the possible effects on apo(a) 
gene expression of Lp(a)-lowering drugs, cytokines 
and hormones among the hapolotypes.
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